Bivalirudin is a synthetic 20-amino acid peptide direct thrombin inhibitor with a molecular mass of 2180 Da and the sequence D-Phe-Pro-Arg-Pro-Gly-Gly-Gly-Gly-Asn-Gly-Asp-Phe-Glu-Glu-Ile-Pro-Glu-Glu-Tyr-Leu. The peptide is rapidly degraded by gastrointestinal proteases and has negligible oral bioavailability; therefore, no approved tablet, capsule, or granule dosage form exists for bivalirudin in any pharmacopoeial jurisdiction. The downstream application scope for this API is restricted to sterile injectable presentations—lyophilized powder for reconstitution, ready-to-dilute vials, and ready-to-use infusion bags—used in parenteral anticoagulation for percutaneous coronary intervention, heparin-induced thrombocytopenia, off-pump coronary artery bypass surgery, and extracorporeal membrane oxygenation. The following application sections are organized by therapeutic indication and manufacturing presentation; each section specifies the relevant compliance standards, addition or dilution ratios, downstream processing conditions, and terminal product type.

Percutaneous coronary intervention requires rapid-onset, reversible anticoagulation to inhibit thrombin-mediated fibrin formation and platelet activation during balloon inflation, stent deployment, and guidewire exchange. Bivalirudin is administered as an initial intravenous bolus of 0.75 mg/kg followed immediately by a continuous infusion of 1.75 mg/kg/h for the duration of the procedure; the infusion may be continued for up to 4 h post-PCI at the prescriber’s discretion. For product preparation, a single-dose vial containing 250 mg bivalirudin is reconstituted with 5 mL sterile water for injection to yield a stock concentration of 50 mg/mL; this stock is then transferred to a 200 mL diluent container of 0.9% sodium chloride or 5% dextrose to produce a 5 mg/mL solution, or to a 500 mL diluent container to produce a 0.5 mg/mL solution for continuous infusion. In hospital pharmacy compounding, the dilution is performed under USP <797> medium-risk aseptic conditions in an ISO 14644-1 Class 5 laminar-airflow workbench located within an ISO Class 7 buffer area; personnel garbing, hand hygiene, and environmental monitoring follow the same chapter. The terminal product type is a sterile infusion bag or pump-compatible syringe assembly for direct use in the cardiac catheterization laboratory. Bivalirudin should not be admixed with other drugs in the same infusion container; the diluted solution contains no preservative, and unused portions are discarded after 24 h.

The upstream finished drug product is manufactured under 21 CFR 210 and 211; the API release specification includes peptide content by high-performance liquid chromatography, related substances, residual trifluoroacetic acid, and bacterial endotoxins per USP <85>. Activated clotting time measurements during PCI typically range between 300 and 350 seconds, but bivalirudin dosing is not titrated to ACT; body-weight–based dosing is used. The 2021 ACC/AHA/SCAI guideline for coronary artery revascularization includes bivalirudin as an anticoagulant option in primary PCI, with particular relevance when heparin-induced thrombocytopenia is present or when direct thrombin inhibition is required.

How Does Bivalirudin Function as a Non-Heparin Anticoagulant in Heparin-Induced Thrombocytopenia?

In type II heparin-induced thrombocytopenia (HIT), platelet-activating IgG antibodies against platelet factor 4/heparin complexes require immediate cessation of unfractionated heparin and low-molecular-weight heparin and transition to a non-heparin anticoagulant. Bivalirudin does not bind platelet factor 4 and does not cross-react with HIT antibodies; it is used as a non-heparin anticoagulant during PCI and as off-label treatment for acute HIT without PCI. The American Society of Hematology (ASH) 2018 guideline recommends non-heparin anticoagulants for acute HIT with thrombosis; the American College of Chest Physicians (ACCP CHEST 2012) guideline addresses direct thrombin inhibitors for HIT management. In PCI patients with HIT, the labeled bivalirudin regimen of 0.75 mg/kg bolus and 1.75 mg/kg/h infusion is administered without prior heparin exposure. For non-PCI HIT treatment, published protocols commonly initiate infusion at 0.15 mg/kg/h to 0.20 mg/kg/h and titrate to an activated partial thromboplastin time (aPTT) ratio of 1.5 to 2.5 times the laboratory control, with aPTT measured every 2–4 h during the first 24 h. The formal FDA-approved renal dose adjustment for PCI reduces the infusion to 1.0 mg/kg/h when creatinine clearance is below 30 mL/min, and to 0.25 mg/kg/h in dialysis-dependent patients; the bolus remains 0.75 mg/kg.

Compounded HIT infusion bags are prepared as 1 mg/mL or 0.5 mg/mL bivalirudin in 0.9% sodium chloride; the terminal product type is a continuous infusion bag for ICU administration through a programmable infusion pump. In 503B outsourcing facilities, aseptic processing follows 21 CFR Part 211, with sterilizing-grade filtration through 0.2 µm membranes, and finished product testing for subvisible particulates per USP <788> and sterility per USP <71>. Laboratory diagnosis of HIT typically uses the 4T score and enzyme immunoassays or serotonin release assay; anticoagulant therapy is initiated after heparin discontinuation and before platelet count recovery. Wide inter-patient variability in aPTT response is documented in clinical registries; published data for this specific configuration are limited, and dose adjustments are frequently required during the first 24 h of therapy.

Off-pump coronary artery bypass grafting presents a procedural anticoagulation challenge when heparin exposure must be minimized or when prior HIT diagnosis mandates non-heparin management. Bivalirudin has been evaluated in this setting as an alternative to unfractionated heparin with protamine reversal. The Society of Thoracic Surgeons (STS) blood conservation guidelines and the European Association for Cardio-Thoracic Surgery (EACTS) guidelines recognize non-heparin anticoagulation in heparin-sensitive patients. Published OPCABG protocols have used an initial bolus of 0.75 mg/kg, an infusion of 1.75 mg/kg/h, and supplemental boluses of 0.3 mg/kg when the activated clotting time falls below 300 s. The prepared infusion bag uses a 250 mg vial diluted in 250 mL 0.9% sodium chloride to 1 mg/mL; the terminal product type includes sterile infusion bags and 50 mL pump syringes for operating-room use. Protamine sulfate does not neutralize bivalirudin; there is no specific antidote, and bleeding management relies on drug cessation and supportive measures.

Intraoperative anticoagulation is monitored with point-of-care ACT instruments such as Hemochron or Medtronic ACT Plus, and target ACT values are adjusted to avoid intraoperative graft thrombosis. Finished injectable manufacturing follows EU GMP Annex 1 (2022) for aseptic fill-finish; the lyophilized powder is tested for container closure integrity per USP <1207> and residual moisture by Karl Fischer titration per USP <921>. The API is supplied with an HPLC assay and related substances specification; batch-to-batch variance in peptide purity is controlled by ICH Q7 GMP for active pharmaceutical ingredients. Published data for OPCABG-specific bivalirudin dosing remain limited to single-center series and retrospective registries.

When Heparin Is Replaced by Bivalirudin in Extracorporeal Membrane Oxygenation

In extracorporeal membrane oxygenation (ECMO), bivalirudin is administered as a continuous intravenous infusion to reduce thrombin activity in the pump, oxygenator, and tubing. This use is off-label but documented in registry data and single-center protocols where unfractionated heparin is contraindicated or ineffective. The Extracorporeal Life Support Organization (ELSO) Anticoagulation Guidelines include bivalirudin as an alternative direct thrombin inhibitor in ECMO. Published dosing protocols commonly start at 0.05 mg/kg/h without a bolus and titrate to aPTT 60–90 s or dilute thrombin time 50–80 s; the infusion bag concentration for adult ECMO is often 1 mg/mL, prepared by diluting 250 mg in 250 mL normal saline. Pediatric circuits may use lower concentrations between 0.05 mg/mL and 0.2 mg/mL depending on patient weight and pump flow; published data for this specific configuration are limited, and no universal target has been validated in randomized trials. Clearance is by proteolysis and renal elimination, and renal function or continuous renal replacement therapy may alter dose requirements.

Circuit performance is monitored through daily oxygenator pressure drop (∆P), post-oxygenator blood gas analysis, and plasma-free hemoglobin; thrombotic failure of the membrane oxygenator requires circuit replacement and is an operational endpoint. Terminal product type is a continuous infusion bag for ICU-administered anticoagulation. For finished product manufacturing, the API must meet bacterial endotoxin limits per USP <85> and particulate matter per USP <788>; aseptic processing follows EU GMP Annex 1 Grade A/B environments and ISO 14644-1 Class 5 cleanroom conditions.

Lyophilized Powder for Injection: Aseptic Fill-Finish and Lyophilization Parameters

Bivalirudin for injection is manufactured as a sterile lyophilized powder in single-dose glass vials, with a labeled content of 250 mg bivalirudin per vial. The formulation contains mannitol as a bulking agent and sodium hydroxide for pH adjustment; the active pharmaceutical ingredient is dissolved, filtered through a 0.22 µm sterilizing-grade membrane, and filled into depyrogenated Type I borosilicate glass vials under Grade A laminar airflow. Freeze-drying requires formulation-specific collapse temperature determination by freeze-drying microscopy; typical peptide lyophilization cycles use primary drying shelf temperatures between -40 °C and -20 °C, chamber pressure of 50–150 mTorr, and secondary drying at +25 °C to +40 °C until residual moisture is below 1.0%. Mannitol crystallization during the freezing step provides a crystalline matrix, but incomplete crystallization or uncontrolled nucleation can cause cake collapse or vial breakage; controlled nucleation at -5 °C to -8 °C is sometimes applied in industrial lyophilizers with shelf temperature uniformity of ±0.5 °C. Specific published cycle data for bivalirudin are limited; therefore, cycle development is performed by differential scanning calorimetry and lyophilizer heat transfer characterization. The addition ratio in clinical use is 250 mg per 5 mL reconstitution fluid, yielding 50 mg/mL; the bulk formulation ratio of mannitol to API is product-specific and determined by cake appearance and reconstitution time.

The terminal product type is a lyophilized cake for reconstitution; product release includes reconstitution time, pH, peptide assay by HPLC, related substances, bacterial endotoxins per USP <85>, sterility per USP <71>, and container closure integrity per USP <1207>. Finished product manufacturing complies with 21 CFR 210/211, ICH Q7 for API GMP, and EU GMP Annex 1 (2022) for sterile medicinal products; the facility environmental monitoring follows ISO 14644-1 Class 5 for fill zones and ISO 14644-2 for monitoring intervals.

Because hospital pharmacy preparation of bivalirudin ready-to-use (RTU) products requires strict aseptic control, 503B outsourcing facilities and health-system central intravenous additive services have established automated compounding lines for these presentations. The RTU product is prepared as a sterile solution of bivalirudin 5 mg/mL in 50 mL 0.9% sodium chloride or 1 mg/mL in 250 mL normal saline; a concentrated 50 mg/mL stock may also be provided for point-of-care activation. The formula addition ratio is governed by USP <797> beyond-use dating: per approved labeling, reconstituted and diluted bivalirudin at 0.5–5 mg/mL is stable at room temperature for 24 h; therefore, batch sizes are planned to match daily catheterization laboratory and intensive care consumption patterns. Aseptic compounding uses closed-system transfer devices, ISO 14644-1 Class 5 workstations, and sterilizing-grade filtration; automated filling machines deliver defined volumes into multi-layer or polyolefin infusion bags. Terminal product type is the ready-to-use infusion bag or prefilled syringe for direct administration without further dilution in the clinical unit. Finished RTU products are tested for subvisible particulates per USP <788>, sterility per USP <71>, and extractables/leachables per USP <1663> and USP <1664>; the container closure system is selected to limit adsorption of the 20-amino acid peptide to polymer surfaces, and compatibility data with 0.9% sodium chloride and 5% dextrose are documented during stability studies.